Zobrazeno 1 - 10
of 165
pro vyhledávání: '"GIMEMA"'
Autor:
Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Luciano Levato, Tamara Intermesoli, Mariella D'Adda, Marzia Salvucci, Fabio Stagno, Giovanna Rege-Cambrin, Mario Tiribelli, Bruno Martino, Monica Bocchia, Michele Cedrone, Elena Trabacchi, Francesco Cavazzini, Ferdinando Porretto, Federica Sorà, Maria Pina Simula, Francesco Albano, Simona Soverini, Robin Foà, Fabrizio Pane, Michele Cavo, Giuseppe Saglio, Michele Baccarani, Gianantonio Rosti
Publikováno v:
Haematologica. 107:2356-2364
We report the final analysis, with a 10-year follow-up, of the phase II study GIMEMA CML 0307 (NCT 00481052), which enrolled 73 adult patients (median age 51 years; range, 18-83) with newly diagnosed chronic-phase chronic myeloid leukemia to investig
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Carolina Terragna, Maria Paola Martelli, Paolo de Fabritiis, Anna Candoni, Alessandra Tedeschi, Giovanni Martinelli, Monia Lunghi, Stefania Paolini, Michele Baccarani, Alfonso Piciocchi, Francesco Fabbiano, Luca Frison, Monica Bocchia, Antonella Vitale, Antonella Fornaro, Cristina Papayannidis, Antonio Cuneo, Piero Galieni, Muriel Granier, Mingyue Wang, Michele Cavo, Robin Foà, Paola Fazi, Marco Vignetti, Chiara Sartor, Roberto M. Lemoli, Fabio Guolo, Simona Soverini, Carmine Selleri, Mariachiara Abbenante, Valentina Robustelli, Giovanni Marconi, Federico Simonetti, Silvia Trappolini, Massimiliano Bonifacio, Patrizia Tosi, Stefano D'Ardia, Zhaoyin Zhu
Tyrosine kinase inhibitors have improved survival for patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). However, prognosis for old or unfit patients remains poor. In the INCB84344-201 (formerly GIMEMA LAL 1811
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532a7ef6c6f327838c21185db5ce9234
http://hdl.handle.net/11567/1078678
http://hdl.handle.net/11567/1078678
Autor:
Luca Maurillo, Adriano Venditti, Maria Teresa Voso, Paolo de Fabritiis, Giovanni Martinelli, Marco Vignetti, Gabriella Storti, Mario Luppi, Francesco Buccisano, Francesco Lanza, Valentina Arena, Giovangiacinto Paterno, Lorella Melillo, Prassede Salutari, Roberto Cairoli, Serena Lavorgna, Paola Fazi, Anna Candoni, Tiziana Ottone, Alfonso Piciocchi, Maria Antonietta Irno Consalvo, Saveria Capria, Raffaele Palmieri, Maria Ilaria Del Principe, William Arcese, Valeria Calafiore
Publikováno v:
Blood advances. 6(8)
The 2017 version of the European LeukemiaNet (ELN) recommendations, by integrating cytogenetics and mutational status of specific genes, divides patients with acute myeloid leukemia into 3 prognostically distinct risk categories: favorable (ELN2017-F
Autor:
Francesca Ronco, Simona Sica, Nicola Di Renzo, Felicetto Ferrara, Robin Foà, Angela Melpignano, Paola Fazi, Alfonso Piciocchi, Catia Bigazzi, Michela Ansuinelli, Alessandra Tedeschi, Nicola Cascavilla, Giovanni Martinelli, Mabel Matarazzo, Marco Vignetti, Francesco Di Raimondo, Francesco Fabbiano, Catello Califano, Sabina Chiaretti, Loredana Elia, Germana Beltrami, Antonella Vitale, L. Santoro
The GIMEMA LAL1509 protocol, designed for adult (≥18-60 years) de novo Ph+ acute lymphoblastic leukemia patients, was based on a dasatinib plus steroids induction - with central nervous system prophylaxis - followed by dasatinib alone in patients i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01e7a7d9661340b7fba81acdaa7c1ff9
http://hdl.handle.net/10807/204734
http://hdl.handle.net/10807/204734
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Cuneo, Antonio, Follows, George, Rigolin, Gian Matteo, Piciocchi, Alfonso, Tedeschi, Alessandra, Trentin, Livio, Perez, Angeles Medina, Coscia, Marta, Laurenti, Luca, Musuraca, Gerardo, Farina, Lucia, Delgado, Alfredo Rivas, Orlandi, Ester Maria, Galieni, Piero, Mauro, Francesca Romana, Visco, Carlo, Amendola, Angela, Billio, Atto, Marasca, Roberto, Chiarenza, Annalisa, Meneghini, Vittorio, Ilariucci, Fiorella, Marchetti, Monia, Molica, Stefano, Re, Francesca, Gaidano, Gianluca, Gonzalez, Marcos, Forconi, Francesco, Ciolli, Stefania, Cortelezzi, Agostino, Montillo, Marco, Smolej, Lukas, Schuh, Anna, Eyre, Toby A, Kennedy, Ben, Bowles, Kris M, Vignetti, Marco, de la Serna, Javier, Moreno, Carol, Foà, Robin, Ghia, Paolo, GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum
We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24b88f44e2262e2f6fabc65579c98fe
https://hdl.handle.net/10668/12372
https://hdl.handle.net/10668/12372
Publikováno v:
Cancer. 123(18):3609-3616
BACKGROUND: In the adult population with newly diagnosed chronic myeloid leukemia (CML), variant translocations are usually not considered to be impairing the prognosis, whereas some additional cytogenetic abnormalities (ACAs) are associated with a n